Open Call SC1-HCO-19-2020: Reliable and Accessible Information on Cell and Gene-Based Therapies

European CommissionCell and gene-based therapies have the potential to treat many debilitating diseases and conditions. However, the pace of their clinical development does not meet public expectations. They face difficulties reaching patients because inter alia the complexity and costs of product development, regulatory hurdles and the non-harmonized procedures for reimbursements. In addition, there are concerns over patient safety due to the use of unproven treatments.

Scope

Proposals should offer well-structured and detailed strategies to convey accurate and up-to-date information on cell and gene-based therapies using multiple contemporary modalities, including a website. The consortium should consist of diverse actors and could include experts in science communication, patients’ representatives, industry, SMEs, clinical and academic researchers as well as the major European learned societies in the field. They should provide expertise across the field of human stem cells, regenerative medicine, genome-editing and gene therapy. All communication material/information should be translated to English and proposals should provide a detailed strategy on the linguistic approach of dissemination in order to reach a large EU audience. The website should be user-friendly and should contain tailored sections dedicated to at least researchers, patients, and the public.

For broader audiences proposals should create a reliable, transparent, accessible resource for patients to make informed decisions and for citizens to have access to scientifically viable information on cell and gene-based therapies, including sex and gender aspects when relevant. Proposals should provide state-of-the-art strategies to engage the public and foresee regular evaluation of whether they reach the targeted audiences. In addition, a series of communication events should be organised, also open to the public, where innovative technologies could be presented and discussed.

For the research community, proposals should create an information source on the practical steps needed for cell and gene-based therapy development. Proposals should provide a one-stop shop on where to seek further information and guidance relating to manufacturing guidelines, regulatory requirements, intellectual property rights, market acceptability and ethical matters. Proposals should provide a strategy on how they will liaise with regulatory agencies (e.g. national agencies, the European Medicines Agency (EMA), the Heads of Medicines Agencies (HMA) network, EUnetHTA network). Finally, proposals should include a realistic sustainability plan which explores how the ownership of the information will be structured, and propose a defined organisation to take responsibility, manage and administer the information, and to which authorities/organisations the information will be delivered at the end of the project. Sustainability should be ensured for at least 5 years after the end of the project.

The Commission considers that proposals requesting a contribution from the EU between EUR 1.5 and 2 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected Impact

  • Better informed decision making by patients and the public, due to objective, accurate and transparent communications of the latest developments and actual treatments available in the field in order to avoid misconceptions
  • Better informed decision making by regulatory and healthcare authorities, due to better access to reliable and updated information, and to stronger synergies and knowledge sharing between decision-makers and other stakeholders including advanced therapies learned societies.
  • Improved products development, by providing the research community and patients with a high-quality information source.

Opening date: 04 July 2019

Deadline: 07 April 2020 17:00:00 Brussels time

Deadline Model: single-stage

Type of action: Coordination and Support Action (CSA)

For topic conditions, documents and submission service, please visit:
https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/sc1-hco-19-2020

PS: Find your partners or consortia preparing a project proposal
If you need help to identify a potential partner with particular competences, facilities or experience, please join and explore (HEALTH IT) SPACE www.healthitspace.eu.

Most Popular Now

Orion Health Supports Professional Recor…

Orion Health is supporting the Professional Record Standards Body's partnership scheme by applying to become a 'quality partner'. The company, which is one of the UK’s leading providers of shared care...

FDA Authorizes Software that Can Help Id…

Today, the U.S. Food and Drug Administration authorized marketing of software to assist medical professionals who examine body tissues (pathologists) in the detection of areas that are suspicious for cancer...

Northumbria Healthcare Picks CliniSys to…

Pathologists at one of England's most innovative trusts have chosen the CliniSys laboratory information system (LIMS) as part of a digital strategy to support its drive to continually improve patient...

Study Finds Telemedicine Appointments Re…

Telemedicine appointments combined with in-person visits significantly reduced the risk of further illness for children with medically complex cases, according to results of a new study by researchers with The...

Contact-Tracing Apps could Improve Vacci…

Mathematical modeling of disease spread suggests that herd immunity could be achieved with fewer vaccine doses by using Bluetooth-based contact-tracing apps to identify people who have more exposure to others...

A Computer Algorithm Called 'Eva' May Ha…

A prescriptive computer program developed by the USC Marshall School of Business and Wharton School of Business of the University of Pennsylvania for Greece to identify asymptomatic, infected travelers...

FDA Clears First Major Imaging Device Ad…

Today, the U.S. Food and Drug Administration cleared the first new major technological improvement for Computed Tomography (CT) imaging in nearly a decade. "Computed tomography is an important medical imaging tool...

Using Internet in Retirement Boosts Cogn…

Using the internet during your retirement years can boost your cognitive function, a new study has found. Researchers from Lancaster University Management School, the Norwegian University Science and Technology and...

AI Tool Improves Accuracy of Breast Canc…

A computer program trained to see patterns among thousands of breast ultrasound images can aid physicians in accurately diagnosing breast cancer, a new study shows. When tested separately on 44,755 already...

Study Shows Trust is still at Heart of N…

A new study has shown that issues surrounding trust are still at the heart of people's reluctance to download and use the NHS App, particularly among Black, Asian and minority...

Time until Dementia Symptoms Appear can …

Researchers at Washington University School of Medicine in St. Louis have developed an approach to estimating when a person who is likely to develop Alzheimer’s disease, but has no cognitive...